Wikisage, the free encyclopedia of the second generation, is digital heritage

Belzutifan

From Wikisage
Revision as of 23:18, 13 August 2021 by Penarc (talk | contribs) (Created page with "Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease. Belzutifan is an inhibitor of hypoxia-inducible facto...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]

ATC